AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 288: G417-G421, 2005; doi:10.1152/ajpgi.00421.2004
0193-1857/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shanahan, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shanahan, F.

THEMES

Physiological Basis for Novel Drug Therapies Used to Treat the Inflammatory Bowel Diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease

Fergus Shanahan

Alimentary Pharmabiotic Centre, Department of Medicine, University College Cork, National University of Ireland, Cork, Ireland

Mechanisms underlying the conditioning influence of the intestinal flora on mucosal homeostasis, including development and function of immune responses, are attracting increasing scientific scrutiny. The intestinal flora is a positive asset to host defense, but some of its components may, in genetically susceptible hosts, become a risk factor for development of inflammatory bowel disease (IBD). It follows that strategies to enhance assets or offset microbial liabilities represent a therapeutic option; therein lies the rationale for manipulation of the flora in IBD. In addition, the diversity of regulatory signalling among the flora and host epithelum, lymphoid tissue, and neuromuscular apparatus is an untapped reservoir from which novel therapeutics may be mined. Moreover, the capacity to engineer food-grade or commensal bacteria to deliver therapeutic molecules to the intestinal mucosa promises to extend the scope of microbial manipulation for the benefit of mankind.

bacteria; intestinal flora; Crohn's disease; ulcerative colitis; mucosal immunity


Address for reprint requests and other correspondence: F. Shanahan, Alimentary Pharmabiotic Centre, Dept. of Medicine, Clinical Science Bldg., Cork Univ. Hospital, Cork, Ireland (E-mail F.Shanahan{at}ucc.ie)




This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
S.K BOHM and W KRUIS
Probiotics: do they help to control intestinal inflammation?
Ann. N.Y. Acad. Sci., August 1, 2006; 1072: 339 - 350.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
K. E. Barrett
A new twist on trefoils. Focus on "TFF3 modulates NF-{kappa}B and a novel regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}"
Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1069 - C1071.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S H Murch
Probiotics as mainstream allergy therapy?
Arch. Dis. Child., September 1, 2005; 90(9): 881 - 882.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.